18F-Prostate Specific Membrane Antigen PET-CT as a potential novel imaging modality for pancreatic cancer: A pilot study

Amsterdam University Medical Center - location VUmc0 个研究点目标入组 15 人开始时间: 2020年5月26日最近更新: 2020年10月26日

适应症

试验速览

暂无简介。

•-Patients aged 18 years or older
•-Diagnosis of suspected pancreatic ductal adenocarcinoma and eligible for surgery
•-Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 15

•-Patients with metastatic PDAC on conventional imaging will be excluded, as current guidelines exclude them from surgery because of no survival benefit.
•-Women who are pregnant and/or or lactating.
•-Medical or psychiatric conditions that compromise the patient’s ability to give informed consent. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
•-Prior radiotherapy to the abdomen and/or thorax.
•-Known hypersensitivity to drugs comparative to 18F-PSMA, or any of their excipients or to any component of 18F-PSMA.
•-Inability to undergo PET-CT scanning (e .g. claustrophobia, weight limits or inability to tolerate lying for the duration of a PET-CT scan (~30 min).
•-Inability to undergo routine MRI or CT scans as part of the diagnostic work up.

发起方

Amsterdam University Medical Center - location VUmc